Formulation design and characterization of a non-ionic surfactant based vesicular system for the sustained delivery of a new chondroprotective agent

AGGARWAL A.K., 2011, Physicochemical characterization and dissolution study of solid dispersions of diacerein with polyethylene glycol 6000, Drug Dev. Ind. Pharm., 37, 1181, 10.3109/03639045.2011.563782

ABDELKADER H., 2010, Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: physicochemical characterization, Pharmazie, 65, 811

ABDELKADER H., 2012, Niosomes and discomes for oculardelivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects, Int. J. Pharm., 433, 142, 10.1016/j.ijpharm.2012.05.011

ATTIA I.A., 2007, Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits, AAPS Pharm. Sci. Tech., 8, 10.1208/pt0804106

ALSARRA I.A., 2005, Proniosomes as a drug carrier for transdermal delivery of ketorolac, Eur. J. Pharm. Biopharm., 59, 485, 10.1016/j.ejpb.2004.09.006

COSTA P., 2001, Modeling and comparison of dissolution profiles, Eur. J. Pharm. Sci., 13, 123, 10.1016/S0928-0987(01)00095-1

DESHMUKH D.B., 2010, Dissolution enhancement of poorly water soluble diacerein by solid dispersion technique, J. Pharm Sci. Res., 2, 734

DASH S., 2010, Kinetic modeling on drug release from controlled drug delivery systems, Acta Pol. Pharm., 67, 217

DEMEL R.A., 1976, The function of sterols in membranes, Biochim. Biophys Acta, 457, 109, 10.1016/0304-4157(76)90008-3

ESSA E.A., 2010, Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes, Asian J. Pharm., 4, 227, 10.4103/0973-8398.76752

GIRIGOSWAMI A., 2006, Fluorescence and dynamic light scattering studies of niosomes membrane mimetic systems, Spectrochim. Acta. A. Mol. Biomol. Spectrosc., 64, 859, 10.1016/j.saa.2005.08.015

GUINEDI A.S., 2005, Preparation and evaluation of reverse phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide, Int. J. Pharm., 306, 71, 10.1016/j.ijpharm.2005.09.023

HONG M., 2009, Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin, J. Control. Release, 133, 96, 10.1016/j.jconrel.2008.09.005

HUNTER D.J., 2007, Review: diacerein is more effective than placebo, J. Evid. Based Med., 12, 74, 10.1136/ebm.12.3.74

JAIN A., 2013, Development of lipid nanoparticles of diacerein, an antiosteoarthritic drug for enhancement in bioavailability and reduction in its side effects, J. Biomed. Nanotechnol., 9, 891, 10.1166/jbn.2013.1580

JAIN C., 1995, Preparation and characterization of niosomes containing rifampicin for lung targeting, J. Microencapsul., 12, 401, 10.3109/02652049509087252

KORCHOWIEC B., 2006, A Langmuir film approach to elucidating interactions in lipid membranes: 1, 2-dipalmitoyl glycero-3phosphoethanolamine cholesterol metal cation systems, Chem. Phys. Lipids, 144, 127, 10.1016/j.chemphyslip.2006.08.005

LI F.T., 2008, Research on surface-modification of Nano-TiO2 by span 60, J. Ceram. Process. Res., 9, 398

MAHALE N., 2012, Niosomes: novel sustained release nonionic stable vesicular systems-an overview, Adv. Colloid. Interface Sci., 183-184, 46, 10.1016/j.cis.2012.08.002

MANOSROI A., 2003, Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol, Colloids Surf. B Biointerfaces, 30, 129, 10.1016/S0927-7765(03)00080-8

MARIANECCI C., 2012, Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models, J. Control. Release, 164, 17, 10.1016/j.jconrel.2012.09.018

MASKI N., 2009, Studies on the preparation, characterization and solubility of β-cyclodextrin-diacerein inclusion complexes, Int. J. Pharm. Pharm. Sci., 1, 121

MOAZENI E., 2010, Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery, J. Microencapsul., 27, 618, 10.3109/02652048.2010.506579

MUZZALUPO R., 2008, Niosomes from α, ω-trioxyethylene-bis (sodium 2-dodecyloxy-propylenesulfonate): Preparation and characterization, Colloids. Surf. B Biointerfaces, 64, 200, 10.1016/j.colsurfb.2008.01.026

NGUYEN M., 1994, Diacerhein in the treatment of osteoarthritis of the hip, Arthritis Rheum., 37, 529, 10.1002/art.1780370413

PARDAKHTY A., 2007, In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin, Int. J. Pharm., 328, 130, 10.1016/j.ijpharm.2006.08.002

PEARLE A.D., 2005, Basic science of articular cartilage and osteoarthritis, Clin. Sports Med., 24, 1, 10.1016/j.csm.2004.08.007

REIS O., 1996, The effect of high extenal pressure on DPPC-cholesterol multilammellar vesicles: a pressure-tuning Fourier transform infrared spectroscopy, Biochim. Biophys. Acta, 1279, 5, 10.1016/0005-2736(95)00233-2

SHARI M.L., 2012

SILVERSTEIN R.M., 2005, 7., 512 p

UCHEGBU I.F., 1995, Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse, Pharm. Res., 12, 1019, 10.1023/A:1016210515134

UCHEGBU I.F., 1998, Non-ionic surfactant based vesicles (niosomes) in drug delivery, Int. J. Pharm., 172, 33, 10.1016/S0378-5173(98)00169-0

WADDAD A.Y., 2013, Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactants, Int. J. Pharm., 456, 446, 10.1016/j.ijpharm.2013.08.040

YOSHIOKA T., 1994, Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85), Int. J. Pharm., 105, 1, 10.1016/0378-5173(94)90228-3